Novel therapies in the treatment of irritable bowel syndrome.
Irritable bowel syndrome (IBS) is characterised by abnormalities in motility, sensation and perception. It is one of the most common conditions encountered in clinical practice, especially by gastroenterologists. Pharmacological treatment of IBS is aimed at the predominant symptom and recent advances in pathophysiology has opened the door to the development of new compounds that target specific receptors. During this review, the most promising investigational and recently approved drugs will be discussed.
Berrada
Driss
D
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Dana 501, 330 Brookline Avenue, Boston, MA 02215, USA.
Lembo
Tony
T
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D029001:Herbal Medicine / Q000379:methods; D006801:Humans; D011985:Receptors, Serotonin / Q000502:physiology; D044406:Receptors, Serotonin, 5-HT3; D044422:Receptors, Serotonin, 5-HT4; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use
D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D017366:Serotonin Receptor Agonists; D044422:Receptors, Serotonin, 5-HT4